Visual Outcomes of Vivity in Patients With High Axial Length (NCT05210569) | Clinical Trial Compass
CompletedNot Applicable
Visual Outcomes of Vivity in Patients With High Axial Length
Canada20 participantsStarted 2022-01-13
Plain-language summary
The objective is to assess the visual outcomes and quality of vision of patients receiving the AcrySof® Vivity Intraocular lens (IOL), when implanted in eyes with high ocular axial length (≥24.5mm), after uneventful cataract surgery.
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Subjects are eligible for the study if they meet the following criteria:
Note: Ocular criteria must be met in both eyes.
Inclusion Criteria:
* Undergoing uncomplicated bilateral cataract surgery with IOL implantation.
* Gender: Males and Females.
* Age: 50 years or older.
* Willing and able to provide written informed consent for participation in the study.
* Willing and able to comply with scheduled visits and other study procedures.
* Motivated for greater degree of spectacle independence vs monofocal IOL.
* Axial length ≥24.5mm in both eyes.
* Planned cataract removal by femtosecond laser.
Exclusion Criteria:
If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
* Ocular comorbidity that might hamper postoperative visual acuity.
* Previous refractive surgery.
* Irregular corneal astigmatism.
* Evidence of keratoconus as per Pentacam.
* Expected post-op VA worse than 20/25 (Snellen).
* Refractive lens exchange.
* Difficulties comprehending written or spoken English language.
* Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).
* Clinically significant or severe ocular surface disease that would affect study measurements based on the investigator's opinion.
* Axial length \<24.5mm.
* Evidence of macular pathology as per optical coherence tomography examination.
The principal investigator reserves the right to declare a patien…